Abstract:OBJECTIVE:Myeloid-derived suppressor cells (MDSCs) contribute to the pathogenesis of systemic lupus erythematosus (SLE), in part due to promoting the survival of plasma cells. FoxO1 expression in monocytic MDSCs (M-MDSCs) exhibits a negative correlation with the SLE Disease Activity Index score. This study aimed to investigate the hypothesis that M-MDSC-specific FoxO1 deficiency enhances aberrant B cell function in aggressive SLE. METHODS:We used GEO data sets and clinical cohorts to verify the clinical significance of FoxO1 expression and circulating M-MDSCs. Using Cre-LoxP technology, we generated myeloid FoxO1 deficiency mice (mFoxO1-/-) to establish murine lupus-prone models. The transcriptional stage was assessed by integrating chromatin immunoprecipitation (ChIP)-sequencing with transcriptomic analysis, luciferase reporter assay, and ChIP-quantitative polymerase chain reaction. Methylated RNA immunoprecipitation sequencing, RNA sequencing, and CRISPR-dCas9 were used to identify N6-adenosine methylation (m6A) modification. In vitro B cell coculture experiments, capmatinib intragastric administration, m6A-modulated MDSCs adoptive transfer, and sample validation of patients with SLE were performed to determine the role of FoxO1 on M-MDSCs dysregulation during B cell autoreacted with SLE. RESULTS:We present evidence that low FoxO1 is predominantly expressed in M-MDSCs in both patients with SLE and lupus mice, and mice with myeloid FoxO1 deficiency (mFoxO1-/-) are more prone to B cell dysfunction. Mechanically, FoxO1 inhibits mesenchymal-epithelial transition factor protein (Met) transcription by binding to the promoter region. M-MDSCs FoxO1 deficiency blocks the Met/cyclooxygenase2/prostaglandin E2 secretion pathway, promoting B cell proliferation and hyperactivation. The Met antagonist capmatinib effectively mitigates lupus exacerbation. Furthermore, alkB homolog 5 (ALKBH5) targeting catalyzes m6A modification on FoxO1 messenger RNA in coding sequences and 3' untranslated regions. The up-regulation of FoxO1 mediated by ALKBH5 overexpression in M-MDSCs improves lupus progression. Finally, these correlations were confirmed in untreated patients with SLE. CONCLUSION:Our findings indicate that effective inhibition of B cells mediated by the ALKBH5/FoxO1/Met axis in M-MDSCs could offer a novel therapeutic approach to manage SLE.

MDSC-derived S100A8/9 contributes to lupus pathogenesis by promoting TLR7-mediated activation of macrophages and dendritic cells

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Myeloid-derived suppressor cells contribute to systemic lupus erythematosus by regulating differentiation of Th17 cells and Treg.

Aberrant CD200/CD200R1 Expression and Function in Systemic Lupus Erythematosus Contributes to Abnormal T-cell Responsiveness and Dendritic Cell Activity

LncRNA XIST Alters the Balance of Peripheral Blood Immune Cells in Systemic Lupus Erythematosus by Regulating the miR-17-92/OFLM4 and CEACAM8 Axis

E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis

Mdscs Enhance Th17 Differentiation and Disease Progression Through Arginase-1 Production in Patients with Systemic Lupus Erythematosus

IRF-8/miR-451a regulates M-MDSC differentiation via the AMPK/mTOR signal pathway during lupus development

Arginase-1–dependent Promotion of T H 17 Differentiation and Disease Progression by MDSCs in Systemic Lupus Erythematosus

TLR9 regulates the autophagy-lysosome pathway to promote dendritic cell maturation and activation by activating the TRAF6-cGAS-STING pathway

MDSCs Participate in the Pathogenesis of Diffuse Pulmonary Hemorrhage in Murine Lupus Through Mtor-Foxo1 Signaling

Myeloid-Derived Suppressor Cells Induce Podocyte Injury Through Increasing Reactive Oxygen Species in Lupus Nephritis.

C-type Lectin Receptor Dectin3 Deficiency Balances the Accumulation and Function of FoxO1-mediated LOX-1+ M-MDSCs in Relieving Lupus-Like Symptoms.

Myeloid-derived suppressor cells shift Th17/Treg ratio and promote systemic lupus erythematosus progression through arginase-1/miR-322-5p/TGF- pathway

MicroRNA-98-5p Inhibits IFI44L-Mediated Differentiation of Dendritic Cells and Activation of Interferon Pathway in Systemic Lupus Erythematosus

FoxO1 Deficiency in Monocytic Myeloid-Derived Suppressor Cells Exacerbates B Cell Dysfunction in Systemic Lupus Erythematosus.

Activation of Tlr7 Increases Ccnd3 Expression Via the Downregulation of Mir-15b in B Cells of Systemic Lupus Erythematosus

Myeloid-Derived Suppressor Cells Shift Th17/Treg Ratio And Promote Systemic Lupus Erythematosus Progression Through Arginase-1/Mir-322-5p/Tgf-Beta Pathway

Cytotoxic CD161−CD8+ TEMRA cells contribute to the pathogenesis of systemic lupus erythematosus

Abnormality and significance of Toll-like receptor 9/myeloid differentiation factor 88 signaling pathway in patients with systemic lupus erythematosus

FoxO1 Deficiency in M‐MDSCs Exacerbates B Cell Dysfunction in Systemic Lupus Erythematosus